GW Pharmaceuticals PLC- (NASDAQ:GWPH) has been given a consensus rating of “Buy” by the fourteen ratings firms that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, eleven have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $214.11.
GWPH has been the subject of several recent analyst reports. Morgan Stanley raised their price target on GW Pharmaceuticals PLC- to $238.00 and gave the company an “overweight” rating in a report on Wednesday, August 7th. Cowen reissued a “buy” rating and issued a $200.00 price target on shares of GW Pharmaceuticals PLC- in a report on Friday, July 26th. Oppenheimer reduced their price target on GW Pharmaceuticals PLC- from $239.00 to $233.00 and set an “outperform” rating for the company in a report on Friday, September 27th. Bank of America reissued a “buy” rating and issued a $218.00 price target on shares of GW Pharmaceuticals PLC- in a report on Wednesday, September 25th. Finally, ValuEngine raised GW Pharmaceuticals PLC- from a “sell” rating to a “hold” rating in a report on Wednesday, September 4th.
GW Pharmaceuticals PLC- stock traded up $1.71 during mid-day trading on Monday, reaching $116.21. 488,912 shares of the company were exchanged, compared to its average volume of 484,894. The company has a debt-to-equity ratio of 0.03, a quick ratio of 7.59 and a current ratio of 8.31. The firm’s 50-day simple moving average is $131.01 and its two-hundred day simple moving average is $159.74. The firm has a market cap of $3.54 billion, a PE ratio of -11.00 and a beta of 2.23. GW Pharmaceuticals PLC- has a twelve month low of $90.14 and a twelve month high of $196.00.
GW Pharmaceuticals PLC- (NASDAQ:GWPH) last posted its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.78) EPS for the quarter, beating the consensus estimate of ($1.74) by $0.96. The business had revenue of $72.04 million during the quarter, compared to analysts’ expectations of $37.28 million. GW Pharmaceuticals PLC- had a negative return on equity of 38.09% and a negative net margin of 101.45%. The company’s quarterly revenue was up 2096.3% compared to the same quarter last year. During the same period last year, the firm earned ($0.25) EPS. As a group, equities research analysts anticipate that GW Pharmaceuticals PLC- will post -3.94 EPS for the current year.
In related news, insider Douglas B. Snyder sold 5,424 shares of GW Pharmaceuticals PLC- stock in a transaction on Monday, August 19th. The stock was sold at an average price of $13.04, for a total transaction of $70,728.96. Following the completion of the transaction, the insider now directly owns 73,740 shares of the company’s stock, valued at $961,569.60. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Douglas B. Snyder sold 3,756 shares of GW Pharmaceuticals PLC- stock in a transaction on Monday, August 12th. The stock was sold at an average price of $13.88, for a total value of $52,133.28. Following the transaction, the insider now directly owns 79,164 shares of the company’s stock, valued at $1,098,796.32. The disclosure for this sale can be found here. Insiders own 3.60% of the company’s stock.
A number of hedge funds have recently modified their holdings of GWPH. Kavar Capital Partners LLC acquired a new position in GW Pharmaceuticals PLC- during the second quarter worth $26,000. Prestige Wealth Management Group LLC acquired a new position in GW Pharmaceuticals PLC- during the second quarter worth $28,000. TCG Advisors LP acquired a new position in GW Pharmaceuticals PLC- during the first quarter worth $29,000. Pathstone Family Office LLC purchased a new position in GW Pharmaceuticals PLC- during the second quarter worth $29,000. Finally, Institutional & Family Asset Management LLC purchased a new position in GW Pharmaceuticals PLC- during the first quarter worth $31,000. 82.93% of the stock is owned by hedge funds and other institutional investors.
GW Pharmaceuticals PLC- Company Profile
GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms.
Recommended Story: Bar Chart
Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.